信达生物与礼来(LLY)签约 独家承接抗癌药国内推广分销业务

金吾财讯
Jun 30

金吾财讯 | 信达生物礼来 (LLY) 联合发布合作公告,双方就 CDK4/6 抑制剂 Verzenios® 阿贝西利签署中国大陆经销推广协议。根据约定,信达生物全权负责该药物在国内的进口、市场宣传、渠道分销与落地推广工作,持有产品独家商业化权益。

礼来作为药品上市许可持有人,持续承担药品全周期生产、供货及后续研发迭代工作。本次合作划分生产端与商业化端权责,依托信达生物国内医药渠道资源扩大药物临床覆盖范围,礼来则持续把控药品生产标准与新药研发管线。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10